CAR T therapy in aggressive lymphoma

According to Dr. Peter Borchmann (University Hospital Cologne, Germany), CD19 CAR T cell therapy has proven efficacy in RR aggressive lymphoma in terms of remission rates, with a significant proportion of complete remissions (ZUMA-1 phase 2 trial: DLBCL 38%; tFL/PMBCL 71%; Juliet phase 2 trial DLBCL: 40%); deep remissions seem to translate into prolonged progression-free survival. “Construct specific side-effects include CRS and neurologic events (NE), which can be managed safely, but requires specific infrastructure and staff training.” The products CTL019 and KTE-C19 are already FDA approved and will hopefully be available in Europe, but Borchmann stressed that follow-ups are too short for final conclusions and further clinical trials are mandatory.

Visit the EHA Learning Center to view the expert interview.

Visit the EHA Learning Center to view the webcast.